Cargando…

2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore

BACKGROUND: Rapid and accurate detection of CPO is crucial to a targeted infection control strategy, as in Tan Tock Seng Hospital (TTSH), a large tertiary hospital in Singapore, where cohorting of CPO colonised patients is driven by PCR-based genotypic identification. A newly released panel for the...

Descripción completa

Detalles Bibliográficos
Autores principales: De, Partha P, Ng, Esme, Pin, Tzer, Lin, Raymond, Hart, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253239/
http://dx.doi.org/10.1093/ofid/ofy210.1727
_version_ 1783373452087918592
author De, Partha P
Ng, Esme
Pin, Tzer
Lin, Raymond
Hart, Tim
author_facet De, Partha P
Ng, Esme
Pin, Tzer
Lin, Raymond
Hart, Tim
author_sort De, Partha P
collection PubMed
description BACKGROUND: Rapid and accurate detection of CPO is crucial to a targeted infection control strategy, as in Tan Tock Seng Hospital (TTSH), a large tertiary hospital in Singapore, where cohorting of CPO colonised patients is driven by PCR-based genotypic identification. A newly released panel for the BD Phoenix system, the CPO Detect panel, includes CPO detection with Amber Class identification, alongside standard Phoenix antibiotic susceptibility testing. We evaluated this system in the context of the TTSH CPO control strategy. METHODS: A total of 201 isolates from CHROMID(®) positive rectal swabs taken as part of inpatient screening, and from clinical samples with confirmed carbapenem resistance, were assayed prospectively between January and April 2018. Ninety-five samples were sampled retrospectively from 2017. CPO genotype was determined using PCR targeting NDM, KPC, oxa48-like, IMI and IMP carbapenemases. Isolates were analysed on the CPO Detect assay in parallel. RESULTS: A broad range of CPO genotypes was achieved and results were comparable in both prospective and retrospective samples. Overall, a concordance of 76% was found between CPO Detect determination of CPO status (both positive and negative) and PCR (238/313 isolates). PCR genotype was in agreement with the Ambler class found by CPO Detect in 151/200 positives (75.5%), 27 samples were not assigned an Ambler class and Ambler class was mismatched in 8 samples. Partial agreement was noted in 17 samples in which CPO Detect indicated a single Ambler class, but PCR identified two carbapanemase genes. CPO Detect outright failed to detect 14/200 PCR positive samples (7%) of which 10 were IMI. CPO Detect did however identify a CPO in a further 54 samples which were PCR negative. CONCLUSION: Compared with PCR, CPO Detect had a sensitivity of 93% in CPO detection and agreement of 75.5% with respect to Ambler class specificity. False negatives were overwhelmingly the IMI genotype. We are continuing to characterise these by further molecular means, as well as the 54 samples found by CPO Detect but PCR negative. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253239
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62532392018-11-28 2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore De, Partha P Ng, Esme Pin, Tzer Lin, Raymond Hart, Tim Open Forum Infect Dis Abstracts BACKGROUND: Rapid and accurate detection of CPO is crucial to a targeted infection control strategy, as in Tan Tock Seng Hospital (TTSH), a large tertiary hospital in Singapore, where cohorting of CPO colonised patients is driven by PCR-based genotypic identification. A newly released panel for the BD Phoenix system, the CPO Detect panel, includes CPO detection with Amber Class identification, alongside standard Phoenix antibiotic susceptibility testing. We evaluated this system in the context of the TTSH CPO control strategy. METHODS: A total of 201 isolates from CHROMID(®) positive rectal swabs taken as part of inpatient screening, and from clinical samples with confirmed carbapenem resistance, were assayed prospectively between January and April 2018. Ninety-five samples were sampled retrospectively from 2017. CPO genotype was determined using PCR targeting NDM, KPC, oxa48-like, IMI and IMP carbapenemases. Isolates were analysed on the CPO Detect assay in parallel. RESULTS: A broad range of CPO genotypes was achieved and results were comparable in both prospective and retrospective samples. Overall, a concordance of 76% was found between CPO Detect determination of CPO status (both positive and negative) and PCR (238/313 isolates). PCR genotype was in agreement with the Ambler class found by CPO Detect in 151/200 positives (75.5%), 27 samples were not assigned an Ambler class and Ambler class was mismatched in 8 samples. Partial agreement was noted in 17 samples in which CPO Detect indicated a single Ambler class, but PCR identified two carbapanemase genes. CPO Detect outright failed to detect 14/200 PCR positive samples (7%) of which 10 were IMI. CPO Detect did however identify a CPO in a further 54 samples which were PCR negative. CONCLUSION: Compared with PCR, CPO Detect had a sensitivity of 93% in CPO detection and agreement of 75.5% with respect to Ambler class specificity. False negatives were overwhelmingly the IMI genotype. We are continuing to characterise these by further molecular means, as well as the 54 samples found by CPO Detect but PCR negative. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253239/ http://dx.doi.org/10.1093/ofid/ofy210.1727 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
De, Partha P
Ng, Esme
Pin, Tzer
Lin, Raymond
Hart, Tim
2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore
title 2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore
title_full 2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore
title_fullStr 2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore
title_full_unstemmed 2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore
title_short 2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore
title_sort 2071. evaluation of bd phoenix™ cpo detect assay for detection of carbapenemase producing organisms in clinical samples in singapore
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253239/
http://dx.doi.org/10.1093/ofid/ofy210.1727
work_keys_str_mv AT departhap 2071evaluationofbdphoenixcpodetectassayfordetectionofcarbapenemaseproducingorganismsinclinicalsamplesinsingapore
AT ngesme 2071evaluationofbdphoenixcpodetectassayfordetectionofcarbapenemaseproducingorganismsinclinicalsamplesinsingapore
AT pintzer 2071evaluationofbdphoenixcpodetectassayfordetectionofcarbapenemaseproducingorganismsinclinicalsamplesinsingapore
AT linraymond 2071evaluationofbdphoenixcpodetectassayfordetectionofcarbapenemaseproducingorganismsinclinicalsamplesinsingapore
AT harttim 2071evaluationofbdphoenixcpodetectassayfordetectionofcarbapenemaseproducingorganismsinclinicalsamplesinsingapore